Anavex Life Sciences Corp. (AVXL)
AVXL Stock Price Chart
Explore Anavex Life Sciences Corp. interactive price chart. Choose custom timeframes to analyze AVXL price movements and trends.
AVXL Company Profile
Discover essential business fundamentals and corporate details for Anavex Life Sciences Corp. (AVXL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Aug 2006
Employees
42.00
Website
https://www.anavex.comCEO
Christopher U. Missling
Description
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
AVXL Financial Timeline
Browse a chronological timeline of Anavex Life Sciences Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.08.
Upcoming earnings on 23 Jul 2026
EPS estimate is -$0.07.
Earnings released on 9 Feb 2026
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%.
Earnings released on 25 Nov 2025
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%.
Earnings released on 12 Aug 2025
EPS came in at -$0.16 falling short of the estimated -$0.13 by -23.08%.
Earnings released on 13 May 2025
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%.
Earnings released on 12 Feb 2025
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%.
Earnings released on 23 Dec 2024
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%.
Earnings released on 6 Aug 2024
EPS came in at -$0.14 surpassing the estimated -$0.15 by +6.67%.
Earnings released on 9 May 2024
EPS came in at -$0.13 matching the estimated -$0.13.
Earnings released on 7 Feb 2024
EPS came in at -$0.11 surpassing the estimated -$0.15 by +26.67%.
Earnings released on 27 Nov 2023
EPS came in at -$0.12 surpassing the estimated -$0.16 by +25.00%.
Earnings released on 8 Aug 2023
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%.
Earnings released on 9 May 2023
EPS came in at -$0.17 surpassing the estimated -$0.18 by +5.56%.
Earnings released on 7 Feb 2023
EPS came in at -$0.17 surpassing the estimated -$0.20 by +15.00%.
Earnings released on 28 Nov 2022
EPS came in at -$0.18 falling short of the estimated -$0.16 by -12.50%.
Earnings released on 9 Aug 2022
EPS came in at -$0.16 falling short of the estimated -$0.15 by -6.67%.
Earnings released on 10 May 2022
EPS came in at -$0.14 surpassing the estimated -$0.16 by +12.50%.
Earnings released on 9 Feb 2022
EPS came in at -$0.14 surpassing the estimated -$0.16 by +12.50%.
Earnings released on 24 Nov 2021
EPS came in at -$0.15 falling short of the estimated -$0.13 by -15.38%.
Earnings released on 12 Aug 2021
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%.
AVXL Stock Performance
Access detailed AVXL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
